Conference Planning Committee

J. Thomas Payte, MD
Conference Chair

Mark W. Parrino, MPA
President
American Association for the Treatment of Opioid Dependence

Carleen Maxwell, MPH
Project Director
American Association for the Treatment of Opioid Dependence

Cheryl Gallagher
Meeting Manager
Talley Management Group, Inc.

Board of Directors
Mark W. Parrino, MPA
President
NY
Robert Holden, CCS
First Vice President
DC
George Stavros, MD
Second Vice President
AZ
Michael A. Rizzi
Treasurer
RI
Carol B. Butler, MA
Secretary
MD

Board Members
Richard Bilangi, MS
CT
Roye T. Brown, MS
LA
Glen Cooper, MA
PA
Eric Ennis, LCSW
CO
Steve Flora
AL
Edward J. Higgins, MA
NJ
Robert B. Kahn, PhD
CA
J anice F. Kauffman, RN
MA
Ira J. Marion, MA
NY
Brant Massman, MBA
NV
Brian McCarroll, DO
MI
Paul McLaughlin, MA
CT
Debbie Sikorski, MA
IL
Keith E. Spare, MS
MO
Gary Wenner, CAP
FL
Terry L. Willis
GA
Ronald A. Winbush, MSSA
OH
Larry Worley, MA
SC

2004 Conference Committees

Accreditation
Lynne McArthur, MA - Chair

Awards
Edward J. Higgins, MA - Chair
Paul McLaughlin, MA
Debbie Sikorski, MA
Keith Spare, MS
George Stavros, MD

Hospitality
Philip Toal, Ed D - Chair
Wanda Pearson, MA
Pat Robertson, RN
Jina Thalmann, MSW

International
Michael A. Rizzi - Chair
Michael Arieli
James Bell
Michael Farrell
Emilia Figueroa, MD
C.P. Hickey
Andrej Kastelic
Icro Maremman, MD

Plenary
Shirley Coletti, DHL - Co-Chair
Nancy Hamilton - Co-Chair
Mark Parrino, MPA

Public Relations
Dan McGill - Chair
Dorrie Burke
William Gouldman

Volunteer
Nora Johnson - Chair
Keith Carpenter
Clara Colon
Aileen LaFont

Workshop
Karol Kaltenbach, PhD - Chair
Andre Benson, MD
Doryne Czechowicz, MD
Vilma Hoffman
Ron Jackson, MSW
Danielle Johnson, MPH
Lynne McArthur, MA
Michael A. Rizzi
Jo L. Sotheran, PhD
Susan Storti, PhD
Pam Waters, MEd
Joan Zweben, PhD
Dear Friends and Colleagues:

Welcome to Orlando, Florida, site of the 20th Anniversary National Conference of the American Association for the Treatment of Opioid Dependence. This very special and historic event is hosted by the Florida Department of Children & Families/Substance Abuse Program Office, the Florida Association for the Treatment of Opioid Dependence, and Colonial Management Group.

We find ourselves at a time of great challenge with unprecedented demands on resources that are limited. This Conference provides an opportunity to build a stronger alliance of the private and public sectors of our field. This alliance will reflect the common goals we all share as we work to increase access to quality treatment of opioid dependence. As you review this Conference Program, you will find that these concerns are clearly addressed in the Pre-Conference Sessions, Workshop Sessions, Plenary Sessions, Poster Presentations, Exhibits, and other related activities.

The Pre-Conference Sessions offered on Saturday and Sunday have been designed to meet the interests and needs of those attending. The Pre-Conference Sessions provide a range of excellent topics, which include access to methadone treatment in the correctional setting, opioid maintenance pharmacotherapy, risk management in the OTP, accreditation, patient advocacy, and research findings.

The conference officially opens with the Welcome Reception to be held poolside on Sunday evening. This event offers time to renew old acquaintances and to establish new relationships.

The Opening Plenary Session on Monday deals with National Drug Policy: Reducing Demand by Improving Treatment Access. On Tuesday, the Middle Plenary Session covers Research to Practice: Using Evidence-Based Methods in Community Treatment and Drug Court Settings. The Closing Plenary Session on Wednesday provides the final touch with Treating the Whole Person: Ensuring the Physical, Mental, and Spiritual Health of Those Recovering from Opioid Dependence.

The excellent range of topics continues with the Workshop Sessions. The Workshop Sessions will incorporate many issues related to opioid dependence including quality improvement, prescription opioid use and abuse, women’s treatment issues, and integrating evidence-based treatment approaches within opioid treatment. In addition, the learning experience will continue as you participate in the Clinic Tours, Hot Topic Round Tables, and Exhibit and Poster Presentations.

Always the highpoint of these conferences is the Awards Banquet on Tuesday evening. The prestigious Nyswander/Dole “Marie” Award will be bestowed on a very special group selected by their peers based on outstanding contributions to our field.

On behalf of the conference committee, thank you for attending the conference. I hope you have a wonderful experience learning and sharing, but do allow some time to relax and sample the wonderful Orlando “attractions”.

Sincerely yours,

J. Thomas Payte, MD
Conference Chair, 2004
GREETINGS!

As Mayor of the beautiful City of Orlando, I would like to extend a personal welcome to the members and guests of the American Association for the Treatment of Opioid Dependence, Inc., attending the 20th National Conference. Orlando is proud to have been selected as host city for conference.

We are fortunate to live in a country that is home to individuals and companies with the vision to continue to build upon our present resources with the goal of enhancing the quality of life in our community for all people.

For those who are first time visitors, you are soon to discover that Orlando's community is rich with opportunities for recreation, cultural entertainment, educational resources, and business enterprises. You will also discover what many others have already noted — that is when it comes to service and hospitality, Orlando is second to none.

Again, thank you for visiting our community. I hope you enjoy learning about our city, meeting our people...and plan on visiting us again soon!

Sincerely,

Buddy Dyer
Mayor
<table>
<thead>
<tr>
<th>DAY</th>
<th>DATE</th>
<th>TIME</th>
<th>EVENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday</td>
<td>October 16</td>
<td>7:00 AM – 4:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 5:30 PM</td>
<td>Buprenorphine, OTP &amp; Office-Based Treatment of Opioid Dependence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:30 AM – 5:30 PM</td>
<td>The Certified Methadone Advocate (CMA) Training Course</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>The Top Accreditation Challenges for OTPs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5:00 PM – 8:00 PM</td>
<td>American Association for the Treatment of Opioid Dependence Open Board Meeting – Board of Directors</td>
</tr>
<tr>
<td>Sunday</td>
<td>October 17</td>
<td>7:30 AM – 6:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 5:30 PM</td>
<td>Opioid Maintenance Pharmacotherapy: A Course for Clinicians</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:00 AM – 12:00 PM</td>
<td>Opioid Treatment in a Corrections Setting – One Community's Response</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:00 AM – 12:00 PM</td>
<td>New Accreditation Initiative: Shared Visions – New Pathways</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:00 AM – 12:30 PM</td>
<td>State Methadone Authorities’ Meeting – Closed Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>State Methadone Authorities’ Meeting – Closed Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>NIDA Clinical Trials Network: Emerging Research Findings to Improve Treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>Risk Management in the OTP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>European Opiate Addiction Treatment Association (EUROPAD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2:00 PM – 5:00 PM</td>
<td>Exhibit Hours</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5:30 PM – 7:30 PM</td>
<td>Welcome Reception</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 PM – 8:30 PM</td>
<td>Methadone Anonymous Meetings</td>
</tr>
<tr>
<td>Monday</td>
<td>October 18</td>
<td>7:30 AM – 4:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 8:30 AM</td>
<td>Continental Breakfast in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 12:30 PM</td>
<td>Exhibits and Poster Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:45 AM – 10:15 AM</td>
<td>Opening Plenary Session – National Drug Policy: Reducing Demand by Improving Treatment Access</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10:30 AM – 12:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:00 PM – 1:30 PM</td>
<td>Lunch (on your own)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:30 PM – 1:30 PM</td>
<td>Exhibit Hall Closed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30 PM – 3:00 PM</td>
<td>Workshop Sessions/Hot Topic Round Tables</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30 PM – 4:30 PM</td>
<td>Exhibits and Poster Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:00 PM – 3:30 PM</td>
<td>Refreshment Break in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:30 PM – 5:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 PM – 8:30 PM</td>
<td>Methadone Anonymous Meetings</td>
</tr>
<tr>
<td>Tuesday</td>
<td>October 19</td>
<td>7:30 AM – 4:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 8:30 AM</td>
<td>Continental Breakfast in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 12:30 PM</td>
<td>Exhibits and Poster Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:45 AM – 10:15 AM</td>
<td>Middle Plenary Session – Research to Practice: Using Evidence-Based Methods in Community Treatment and Drug Court Settings</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10:30 AM – 12:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:00 PM – 1:30 PM</td>
<td>Lunch (on your own)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:30 PM – 1:30 PM</td>
<td>Exhibit Hall Closed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30 PM – 3:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30 PM – 4:30 PM</td>
<td>Exhibits and Poster Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:00 PM – 3:30 PM</td>
<td>Refreshment Break in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:00 PM – 4:30 PM</td>
<td>Poster Author Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:00 PM – 9:30 PM</td>
<td>Awards Banquet</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:30 PM – 10:30 PM</td>
<td>Methadone Anonymous Meetings</td>
</tr>
<tr>
<td>Wednesday</td>
<td>October 20</td>
<td>7:00 AM – 1:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:00 AM – 8:00 AM</td>
<td>Continental Breakfast</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 9:30 AM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:45 AM – 11:15 AM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11:30 AM – 12:45 PM</td>
<td>Closing Plenary Session – Treating the Whole Person: Ensuring the Physical, Mental, and Spiritual Health of Those Recovering from Opioid Dependence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 3:30 PM</td>
<td>Clinic Tours</td>
</tr>
</tbody>
</table>
The Drug Addiction Treatment Act of 2000 (PL106-310, Section 3502) permits physicians who are trained or experienced in opioid addiction treatment to obtain waivers to prescribe certain narcotic drugs in Schedule III, IV, or V of the Controlled Substances Act, in their office practices or in an opioid treatment program (OTP) clinic setting, for the treatment of opioid dependence. Both buprenorphine and the combination of buprenorphine with naloxone have been approved by the Food and Drug Administration (FDA) for use in detoxification and maintenance treatment of opioid dependence.

Buprenorphine/naloxone may be dispensed from opioid treatment programs. New federal regulations also allow for the dispensing of buprenorphine/naloxone from opioid treatment programs under the same policies and procedures as methadone.

The target audience includes physicians with experience and/or interest in treating opioid dependence, and medical directors of opioid treatment programs. Physicians, program directors, and masters level health care personnel are also encouraged to participate.

**Educational Objectives**

After participating in this course, you should be able to describe:

- Models of successfully integrating buprenorphine/naloxone into care in an opioid treatment program
- The prerequisites for a physician to begin to prescribe buprenorphine in office-based practice
- The clinically relevant pharmacological characteristics of buprenorphine
- Factors to consider in determining whether a patient is an appropriate candidate for office-based treatment
- Induction and maintenance protocols
- Strategies for integrating psychosocial care with office-based pharmacological treatment
- Treatment strategies for management of acute pain in patients receiving buprenorphine treatment for opioid dependence

As part of the requirements to get the waiver, physicians without specified experience must complete not less than 8 hours of training. Physicians who complete this 8-hour course will meet the training qualification under the new law and will receive a certificate of attendance suitable to send to the Secretary of Health and Human Services (HHS) along with the request for the waiver. If you give the American Society of Addiction Medicine (ASAM) permission to do so, ASAM will report your name directly to the Secretary of HHS within 4 weeks of the program, if you have completed the full 8 hours, eliminating the need for you to send the certificate of attendance.

Because ASAM will be called upon to confirm that participants have attended a full 8 hours, you must bring a photo identification to show as part of the sign-in process, you must confirm your attendance with your signature at the beginning of both the morning and the afternoon sessions, and you must sign out at the conclusion of the program. Certificates of attendance will be mailed to you within 4 weeks of the program. Note that latecomers may not be eligible for a certificate of attendance if ASAM cannot confirm 8 hours of attendance.

**Sponsored by the American Society of Addiction Medicine.**

**Supported by an unrestricted continuing medical educational grant provided by Reckitt Benckiser.**
THE CERTIFIED METHADONE ADVOCATE (CMA) TRAINING COURSE

Additional Fees Apply – See Below for Registration Information

TIME: 8:30 AM – 5:30 PM

Frederick W. Christie, MA
AFIRM
Long Island, NY

James P. Connolly, CMA
PA-NAMA
Newtown, PA

Walter Ginter, CMA
NAMA
Westport, CT

Ray Hylton, RN
CSAT/PT
Rockville, MD

Herman Joseph, PhD
NAMA
New York, NY

Thomas Kresina
NIDA/CSAT
Rockville, MD

Stewart Leavitt, PhD
Addiction Treatment Forum
Glenview, IL

J. Thomas Payte, MD
Colonial Management Group
Orlando, FL

Joycelyn Woods, MA
NAMA
New York, NY

It is the view of the National Alliance of Methadone Advocates (NAMA) that everyone who supports the use of methadone treatment is a potential methadone advocate. We encourage all supporters of methadone treatment, patient and non-patient, to become Certified Methadone Advocates (CMAs) so that all energies directed toward the advancement of methadone treatment produce positive results.

This course fulfills the training requirement for Certification as a Methadone Advocate. It is designed for non-clinicians and involves 8 hours of rigorous training. The course equips participants with the tools they will need to succeed in the struggle to have methadone maintenance treatment universally accepted as the “gold standard” for addiction treatment.

With these goals in mind the course presentation is as follows:

- Addiction and Methadone - scientifically accurate yet in language understandable to the non-clinician.
- Regulations and Accreditation – explained by experts from the Center for Substance Abuse and Treatment (CSAT) who understand the systemic complexities.
- Methadone Mythology - exposing the myths surrounding methadone treatment.
- The Certified Methadone Advocate (CMA) - the mechanism of certification and how it will professionalize those committed to advocacy; includes advocacy on the Net and Methadone Anonymous.
- Methadone Stigma – a history of administrative and community prejudice directed at methadone patients, plus analyses of possible solutions.
- Office-Based Treatment Model – whether buprenorphine or methadone, an advance for patients and an administrative hurdle for implementation.
- Hepatitis C - the second most important subject for all methadone patients.

There is a separate registration fee of $100.00 for this pre-conference event. The fee includes all materials, 2005 membership in NAMA, and the application for CMA. Beverages and light snacks served throughout the training. The training will adjourn between 12:00 PM and 1:00 PM. Lunch is not provided.

Candidates for certification must register with NAMA prior to the conference. Registration information available at: www.methadone.org/registration.doc

On-site registration will be between 7:00 AM and 8:00 AM at the NAMA table in the lobby. NAMA cannot guarantee a place to anyone who is not pre-registered.

Sponsored by the National Alliance of Methadone Advocates (NAMA).

Supported by the Substance Abuse and Mental Health Services Administration, Center of Substance Abuse Treatment, and Mallinckrodt, Inc.

THE TOP ACCREDITATION CHALLENGES FOR OTPs

TIME: 1:00 PM – 5:00 PM

Scott Chavez
National Commission on Correctional Health Care
Chicago, IL

John Cox
Division of Alcohol & Substance Abuse Washington Department of Social & Health Services
Olympia, WA

Bettye Harrison
Commission on Accreditation of Rehabilitation Facilities
Tucson, AZ

Tim Stockert
Council on Accreditation for Children and Family Services
New York, NY

Megan Marx
Joint Commission on Accreditation of Healthcare Organizations
Littleton, CO

Marie Peoples
Division of Alcohol & Drug Abuse
State of Missouri Department of Mental Health
Jefferson City, MO

Lisa Glass
Council on Accreditation for Children and Family Services
New York, NY

This session will address the accreditation process of each accrediting body, and the context in which opioid treatment programs have encountered and dealt with key challenges to becoming accredited. Information will be presented regarding the most commonly cited standards in opioid treatment programs.

Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

*NOT APPROVED FOR CME CREDITS
This course will serve as a primer for clinicians working in methadone treatment programs. Physicians, physician’s assistants, nurses, and other interested personnel who want to learn about opioid treatment practices are encouraged to attend.

The new and expanded curriculum will include epidemiology, opioid pharmacology/neurobiology, evidence-based treatment options, patient assessment/selection, special populations, induction and maintenance protocols, pain management, drug to drug interactions, adverse effects, methadone deaths, managing medical/psychiatric problems, drug testing, regulatory issues, an accreditation update, and an overview of buprenorphine. Participants will receive a comprehensive syllabus and resource materials.

Four experienced opioid treatment medical directors will present, in lecture and question/answer format, focusing on information essential for the clinician to function in an opioid treatment program. To integrate the learning objectives, the presenters will provide case discussions focusing on challenging cases that will facilitate the didactic principles.

The $150.00 registration fee includes a morning coffee service, afternoon luncheon, and the evening’s Welcome Reception.

Sponsored by the American Association for the Treatment of Opioid Dependence and the American Society of Addiction Medicine in cooperation with the American Academy of Addiction Psychiatry and the American Osteopathic Academy of Addiction Medicine.

Supported by the National Institute on Drug Abuse.

In 2001 Orange County formed the County Commissioner’s Jail Oversight Commission to address issues in the Orange County jail. A mental health and substance abuse subcommittee was formed, and the issue of treatment for inmates on methadone maintenance was identified as one area of focus.

The Center for Drug Free Living and Orange County partnered to bring continued methadone treatment to incarcerated inmates who were already affiliated with a methadone program. The challenges and solutions will be the focus of this presentation.

Participants will have the opportunity to learn how one community came together to successfully address an issue in the county jail that had ramifications for the jail community and the community at large.

Pam Steinke will provide an overview of the Jail Oversight Commission’s work to enhance substance abuse and mental health services in the Orange County jail. Babette Hankey and Pam Steinke will provide an overview of the work the two agencies engaged in to develop a working model for this program. Dr. Seikel and Dr. Ellis will provide an overview of the medical aspects of this program and the future of opioid dependency treatment in the Orange County jail.

Sponsored by the Center for Drug Free Living and the Orange County Department of Corrections.
NEW ACCREDITATION INITIATIVE: SHARED VISIONS – NEW PATHWAYS

TIME: 9:00 A.M – 12:00 P.M  Scotland C

Mary Cesare-Murphy  Megan Marx
Joint Commission on Accreditation  Joint Commission on Accreditation
of Healthcare Organizations  of Healthcare Organizations
Oakbrook Terrace, IL  Littleton, CO

Shared Visions – New Pathways is the culmination of an intensive review and re-design of the Joint Commission’s accreditation process that began in 1999 as a continuous improvement initiative. The result is a complete paradigm shift from a process focused on survey preparation and score achievement to one of continuous systematic and operational improvement by focusing to a greater extent on the provision of safe, high quality care, treatment, and services.

This Pre-Conference Workshop will focus on the changes brought about by Shared Visions – New Pathways including:

• Acquisition and use of more in-depth information about health care organizations to help focus the survey.
• Application of that information to the accreditation process.
• More timely, efficient, and effective communications between JCAHO and health care organizations.
• Reformating and clarifying standards to focus more directly on safety and quality.
• A more continuous accreditation process to facilitate an organization’s incorporation of the standards into daily operations.
• Accreditation decisions.
• Follow-up after the survey.
• Survey reporting.

At the end of this workshop, participants will be able to:

• Describe changes to the survey process based on Shared Visions – New Pathways.
• Understand how the standards and survey process will be applied to the OTP.

This workshop is open to all Joint Commission accredited opioid treatment programs. Please register on-site at the JCAHO Registration Desk.

Sponsored by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO).

STATE METHADONE AUTHORITIES’ MEETING  (CLOSED SESSION – FOR STATE AND FEDERAL OFFICIALS)

TIME: 9:00 A.M – 12:30 P.M  Ireland B

Arlene Stanton, PhD  Nicholas Reuter, MPH  Robert Lubran, MS
Center for Substance Abuse Treatment  Center for Substance Abuse Treatment  Center for Substance Abuse Treatment
Rockville, MD  Rockville, MD  Rockville, MD

Ray Hylton, RN
State Methadone Authorities
Rockville, MD

Center for Substance Abuse Treatment staff and State Methadone Authorities (SMAs) will discuss a variety of topics of interest to both the Substance Abuse and Mental Health Services Administration (SAMHSA) and the states including the newly released buprenorphine treatment protocols, the impact of the availability of buprenorphine treatment on state policies and procedures, confidentiality issues, the expansion of a pilot project focused on HCV training, and the progress made in defining the issues concerning methadone-related deaths.

Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

STATE METHADONE AUTHORITIES’ MEETING  (CLOSED SESSION – FOR STATE METHADONE AUTHORITIES)

TIME: 1:00 PM – 5:00 PM  Ireland B

State Methadone Authorities

The State Methadone Authorities will convene for the presentation of the results of comprehensive research funded by the Robert W. Johnson Foundation and conducted by Deborah Podus, PhD, from the University of California at Los Angeles. This study traces the impact of methadone treatment on a variety of systems since its inception. The SMAs will also have the opportunity to discuss issues of interest to the States.

Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.
PRE-CONFERENCE SESSIONS

Sunday, October 17

NIDA CLINICAL TRIALS NETWORK:
"Emerging Research Findings To Improve Treatment"

TIME: 1:00 PM – 5:00 PM

Session Chairs:

Ron Jackson, MSW
Evergreen Treatment Services
Seattle, WA

George Woody, MD
Department of Psychiatry, University of Pennsylvania
Philadelphia, PA

The National Drug Abuse Treatment Clinical Trials Network (CTN) is a cooperative undertaking of NIDA, university drug abuse scientists, and community treatment providers in which researchers and practitioners work together to test research-based treatments in community settings. Currently, 17 regional research and training centers are receiving funding, and are linked to more than 125 community treatment programs.

The objectives of the pre-conference session are to:

1. Provide an overview of the development and implementation of the National Drug Abuse Treatment Clinical Trials Network.
2. Present findings from the “wave 1” clinical trial protocols, describe studies that are currently underway, and discuss plans for future studies.
3. Discuss the challenges and opportunities associated with programs that blend research and practice, including ethics and confidentiality issues, and lessons that have been learned from the collaboration between academic researchers and community treatment providers.
4. Discuss plans for disseminating findings from the CTN studies and training materials and science-based treatment manuals.

This session will provide an opportunity for interactive discussion with the conference participants. Handouts and resource materials will be available to the participants in this session.

1:00 pm

Overview of the Clinical Trials Network

George Woody, MD
Principal Investigator Delaware Valley Node
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA

2:00 pm

Preliminary Findings from Clinical Trials Network Protocols

Buprenorphine/naloxone in the detoxification of opiate dependent patients

Walter Ling, MD
Principal Investigator, Pacific Region Node, NIDA CTN
Director, Integrated Substance Abuse Programs, Los Angeles, CA
Professor of Psychiatry and Biobehavioral Sciences, UCLA

Motivational enhancement and motivational interviewing to improve treatment engagement and outcome

Sam Ball, PhD
Co-Investigator, New England Node, NIDA CTN
Yale University School of Medicine
Connecticut VA Healthcare Center
New Haven, CT

Motivational incentives to enhance drug abuse recovery

Maxine Stitzer, PhD
Principal Investigator, Mid-Atlantic Node, NIDA CTN
Professor, Department of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Baltimore, MD

3:00 pm

The Clinical Treatment Provider and Policy Perspectives on Participating in Research

An integral part of the mission of the CTN is to develop a bi-directional partnership between researchers and providers. The clinical treatment provider and policy perspectives will be useful to all programs considering involvement in research studies and to the researcher who wants to design studies that will lead to improvements in drug addiction treatment

Violanda Nunez, LISW
Southwest Node
Executive Director, Ayudantes, Inc.
Santa Fe, NM
RISK MANAGEMENT IN THE OTP

Barbara A. M. Maloney, Esq.
Barbara A. M. Maloney, Esq., PLLC
Auburn, NH

Catherine H. O’Neill, Esq.
Legal Action Center
New York, NY

Time: 1:00 PM – 5:00 PM

Health care risk management programs emerged 30 years ago in direct response to the malpractice crisis of the 1970s. The programs were specifically developed as loss prevention techniques for the risks associated with accidental losses facing health care organizations. AATOD has concluded that methadone treatment programs can benefit from an effective risk management training program, in ways that are similar to the benefits that have accrued to other health care providers. In addition, accreditation has encouraged individualized patient care and developed opportunities for programs to better organize their administrative structure, further supporting risk management as well.

This Pre-Conference Session will introduce OTP practitioners to the key elements of a risk management program and how they can be directly applied to work with methadone treatment programs. Programs will also get the most current information available about leading legal risks to methadone treatment program operations in addition to a discussion of some critical court cases that have affected methadone treatment programs at present and can have an effect in the future.

The session will consider topics as they apply to specific issues including:

- What happens to the program when adverse events occur
- Scope of risk management
- Common risk identifiers
- Setting priorities, facts to consider
- Risk prevention
- Risk minimization
- Claims management
- Developing proactive legal strategies
- Patients’ confidentiality rights
- Methadone treatment programs’ liability for patients’ actions

Supported by David Szerlip and Associates.
Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

American Association for the Treatment of Opioid Dependence
PRE-CONFERENCE SESSIONS

Sunday, October 17

EUROPEAN OPIATE ADDICTION TREATMENT ASSOCIATION (EUROPAD)
Heroin Addiction and Related Clinical Problems

TIME: 1:00 PM – 5:00 PM

Chairmen: Icro Maremmani, MD Pisa, Italy, EU Marc Reisinger, MD Brussels, Belgium, EU

Scotland A

1:00 PM
When Enough is Not Enough. Research and Practice Supporting Prescription of Clinically Effective Doses in Excess of 100 mg in Methadone Maintenance Treatment
M. Shinderman, Chicago, IL, USA

1:20 PM
Attention Deficit Hyperactive Disorder (ADHD) and Addiction Risks (new data)
J.J. Deglon, Geneva, Switzerland

1:40 PM
Psychopathology and Quality of Life in 1-Year Buprenorphine or Methadone Treated Heroin Addicts
I. Maremmani, Pisa, Italy

2:00 PM
Psychopathology and Methadone Maintenance: A 2-Year Follow-Up
P.P. Pani, Calgiari, Italy

2:20 PM
IST Project Fact Sheet Intelligent Intra-Oral Medicine Delivery Micro-System to Treat Addiction and Chronic Diseases. Funded Under 6th FWP (Sixth Framework Programme)
M. Arieli, Tel Aviv, Israel

2:40 PM
Quality Assessment for MM Patients in Clinical Setting
M. Lovrecic, Ljubljana, Slovenia

3:00 PM
HIV and Drug Abuse Problems in Russia
V. Lisenko, Moscow, Russia

3:20 PM
Comprehensive Methadone Assisted Treatment Model
A. Katchelov, O. Angelova, Sofia, Bulgaria

3:40 PM
Alcohol Abuse in Heroin Addicts
M. Pacini, Pisa, Italy

4:00 PM
The Opening of a New Clinical Institute in France. Results 1-Year After
B. Lepère, M. Sanchez, W. Lowenstein, Paris, France

4:20 PM
Discussion

5:00 PM
End of Forum

In collaboration with Heroin Addiction and Related Clinical Problems and Italian Journal on Addictions.

Welcome Reception

Sunday, October 17, 2004

The Welcome Reception affords all participants the opportunity to make new professional and personal acquaintances, as well as to enjoy some relaxing time with old friends and colleagues not seen for too long. The reception will be held poolside at the Wyndham Palace Resort & Spa.

The Welcome Reception is supported through a grant from Cebert Pharmaceuticals, Inc.
Continental Breakfasts and Coffee Breaks will be served each day and are supported by the following:

**Monday, October 18, 2004  Exhibit Hall**

*7:30 AM Continental Breakfast - Creative Socio-Medics*

*3:00 PM Coffee Break - San Diego Reference Laboratory*

**Tuesday, October 19, 2004  Exhibit Hall**

*7:30 AM Continental Breakfast - Addiction Management Systems, Inc.*

*3:00 PM Coffee Break - O. Berk Company of New England and Kols Containers, Inc.*

**Wednesday, October 20, 2004  Hampton Court Assembly**

*7:00 AM Continental Breakfast - VistaPharm, Inc.*

### EXHIBITION AND POSTER SESSIONS

The 2004 Conference is another record setting event. This year’s 20th Anniversary Conference, in Orlando, Florida, promises to offer an exciting interaction between conference registrants and exhibitors. Visiting the Exhibit Hall is a great opportunity for everyone in attendance to interact with professionals who are totally devoted to methadone maintenance and treatment worldwide. Posters will be on display during the entire conference. We hope to see you there.

**Hours**

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, October 17, 2004</td>
<td>2:00 PM to 5:00 PM</td>
</tr>
<tr>
<td>Monday, October 18, 2004</td>
<td>7:30 AM to 12:30 PM</td>
</tr>
<tr>
<td>Monday, October 18, 2004</td>
<td>1:30 PM to 4:30 PM</td>
</tr>
<tr>
<td>Tuesday, October 19, 2004</td>
<td>7:30 PM to 12:30 PM</td>
</tr>
<tr>
<td>Tuesday, October 19, 2004</td>
<td>1:30 PM to 4:30 PM</td>
</tr>
</tbody>
</table>

The Poster Author Session will take place in the Exhibit Hall on Tuesday, October 19, 2004 from 3:00 p.m. to 4:30 p.m.

*Please see page 17 for the complete listing of the Poster Presentations and page 23 for the Exhibitor listing.*
The Goals and Objectives of the American Association for the Treatment of Opioid Dependence 2004 National Conference are:

- To identify and provide new information of critical importance to the field
- To examine and evaluate the implications of new information for clinicians, administrators, and policy makers
- To demonstrate techniques for improving clinical and program administration

OPENING PLENARY SESSION
National Drug Policy: Reducing Demand by Improving Treatment Access
8:45 AM - 10:15 AM
Great Hall North/Center

Speakers:

J. Thomas Payte, MD, Conference Chair, Corporate Medical Director, Colonial Management Group, Orlando, FL

Kenneth DeCerchio, MSW, Director, Substance Abuse Program Office, Florida Department of Children and Family Services, Tallahassee, FL

Mark W. Parrino, MPA, President, American Association for the Treatment of Opioid Dependence, New York, NY

The opening plenary session will launch the 20th year of AATOD, providing the latest information to all conference attendees about AATOD’s national policies. The plenary session will also provide current information about trends in substance abuse in the state of Florida in addition to focusing on how SAMHSA/CSAT and the White House Office of National Drug Control Policy (ONDCP) balances the availability of illegal drugs with the need to improve treatment and increase access to care. Dr. H. Westley Clark is one of the nation’s leading voices in promoting the need for evidence-based treatment practices and the reduction and demand for illegal drugs. Ms. Colston will present ONDCPs current initiatives and discuss the impact on the treatment system.

WORKSHOP SESSIONS
Workshops will offer a chance to review the latest treatment data and health care policies, examine their implications for our patients, and strengthen the skills needed to improve the quality of services.

Basic Track: This year we will again be offering a special sequence of workshops designed to act as a refresher for seasoned professionals and to meet the needs of individuals who are new to this field. Those who attend all six sessions listed will receive a special certificate of completion.

Basic Track Workshop Sessions: A1, B1, C1, D1, E1, and F1

A – 1
Medical Aspects of Methadone
Great Hall North
Judith Martin, MD, 14 Street Clinic, Oakland, CA
This workshop is part of the Basic series intended for entry level counselors. It will review the elements of opioid agonist treatment, such as dose, side effects, and duration of MMT. It will cover pharmacologic aspects such as half-life, receptor site, blood level, and rapid metabolizer. It is intended to provide a language to engage the patient who is concerned about his or her medication in a therapeutic way.

* Note: Basic Track

A – 2
Interface Between Pharmacotherapies and Co-Occurring Disorders in Opioid Dependent Patients
Great Hall Center
Laura McNicholas, MD, VIA Medical Center, Philadelphia, PA; Carlos Traba, MD, University of Pennsylvania Health System – Treatment Research Division, Philadelphia, PA
This workshop will describe both the historical background to the use of psychoactive medications with patients in opioid maintenance therapy and the current and future outlook for psychopharmacotherapies for patients with co-occurring mental health disorders. Particular emphasis will be placed on the treatment of depressed conditions in opioid dependent patients.

A – 3
Residential Treatment: “What’s Methadone Got to Do With It”
Ireland A/B/C
Siara Andrews, PsyD, UCSF-SFGH; San Francisco, CA; Yong Song, PhD, SFGH-Ward 93, San Francisco, CA; Steve Myers, MC, Walden House, San Francisco, CA
This workshop presents research-investigating treatment of methadone maintenance patients in residential treatment. This practical workshop will provide ideas for treatment expansion and methodology for building ties between methadone programs and therapeutic communities, with the goal of improving the effectiveness of care for opioid dependence.

A – 4
Maintaining Accreditation: Meeting the Challenges of Compliance
England
Megan Marx, MPA, Joint Commission on Accreditation of Healthcare Organizations, Littleton, CO; Mary Cesare-Murphy, PhD, Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL
This workshop will provide a review of commonly cited Joint Commission accreditation standards and discuss compliance strategies. Presenters will also share tips for completing the periodic performance review and how to use it as a risk management resource. Finally, presenters will address the use of data to improve program performance.

A – 5
Addressing the Co-Occurring Problems of Intimate Partner Violence and Illicit Drug Use Among Women in MMTPs
Scotland A/B/C
Louisa Gilbert, CSW, Columbia University, Social Intervention Group, New York, NY; Randy Seevard, MD, Beth Israel Medical Center - MMT, New York, NY; Brenda M. Ray, NP, Beth Israel Medical Center - MMT, New York, NY
This workshop presents the complex relationship between intimate partner violence and illicit drug use among women in MMTPs and to discuss a novel, integrated treatment approach that may address the co-occurring problems of intimate partner violence and illicit drug use in this population.
WORKSHOP SESSIONS

1:30 PM – 3:00 PM

Bereavement: The Culture of Mourning Among Opiate Addicted Individuals

Angela Kirk, PhD, Compdrug Corp., Columbus, OH; Kevin Jay Carroll, MPH, Compdrug Corp., Columbus, OH

This seminar will explore the unique issues faced by bereaved opiate dependent individuals. The stages of grief, an overview of the research and how to identify the readiness for grief work will be presented. In addition, how to implement a grief support group will be discussed.

Growing Your Own Comprehensive Training Program

Robert C. Lambert, MA, Connecticut Counseling Centers, Inc., Norwalk, CT

This workshop will demonstrate how to design and implement a cost-effective in-house training program. The presenter will de-mystify the process of designing a curriculum and give the participants a "nuts and bolts" understanding of how to implement their own training program to meet their unique training needs and credentialing goals.

Treatment on Demand: Learn about Network for the Improvement of Addiction Treatment from the Brandywine Counseling and Acadia Hospital Perspective

James Harrison, LPC, Brandywine Counseling Inc., Wilmington, DE; Scott Farnum, MS, Acadia Hospital, Bangor, ME; Lynn Madden, MPA, Acadia Hospital, Bangor, ME

Learn to improve patient access and retention through process improvement, data-driven decision making, and better understanding of the customer. Presenters will discuss their participation in the Paths to Recovery/Strengthening Treatment Access & Retention initiative of the Robert Wood Johnson Foundation and SAMHSA.

HOT TOPIC ROUND TABLES

1:30 PM – 3:00 PM

Hot Topic Round Tables are facilitated discussions that focus on current controversial issues in an informal context. Meet with your colleagues as you learn, challenge, support and share your views with others who may have similar or different opinions, experiences, or interests. Engage in one or more of these facilitated discussions.

- Achieving Accreditation
  Megan Marx, MPA
  Sapphire

- Methadone Maintenance Patients in the Recovery Community
  Lisa Majer-Torres
  Diamond

- Methadone Anonymous: Positive Benefits to Clinics, Patients, and Diminishing the Stigma within the Community at Large
  Frederick W. Christie, MA
  Emerald

- Administrative Detox: Ethical Dilemmas and Constructive Strategies
  Trusandra Taylor, MD
  Cloister North

- Proactive Responses to Lack of OTP in Correction Facilities
  Jina K. Thalmann, LCSW
  Cloister South

- Buprenorphine Regulations for OTP: Double Standards?
  Allan Cohen, MA
  Senate/Gallery

- Retaining Staff: Challenges and Solutions
  Kate Vandegrift, LPC
  Scribe/Knave

*NOT APPROVED FOR CME CREDITS*
WORKSHOP SESSIONS

3:30 PM - 5:00 PM

Monday, October 18, 2004

B - 1
Assessment and Treatment Planning for the Clinician

Great Hall North

Cynthia Banfield-Weir, LICSW, Community Health Care, Chicopee, MA

As opioid treatment providers meet accreditation standards, clinicians are being asked to demonstrate clinical competence through their ability to complete an assessment and develop a treatment plan that describes an outline for change. This workshop is designed to assist clinicians in assessment and treatment planning.

* Note: Basic Track

B - 2
An NTP Affiliated Office-Based Opiate Treatment (OBOT) Program in a Public Health Setting

Great Hall Center

Alice Gleghorn, PhD, San Francisco Department of Public Health Community Behavioral Health Services, San Francisco, CA; David Hersh, MD, UCSF, San Francisco, CA; Sharon Kotabe, PharmD, Community Health Network of San Francisco, San Francisco, CA

The San Francisco Department of Public Health OBOT program provides office-based opiate addiction treatment with methadone and buprenorphine to opiate dependent individuals. The presentation will include: program overview; background of its design and implementation; clinical review of buprenorphine/methadone treatment protocols; and issues specific to community-based pharmacy services. Preliminary compliance and outcomes indicators will be discussed.

B - 3
Even Borderlines Get the Blues: Treating the Person, Not Just the Problem

Ireland A/B/C

Neil Bomar, MD, Memphis Center for Research and Addiction Treatment, Memphis, TN; Anne Knight, LCSW, Memphis Center for Research and Addiction Treatment, Memphis, TN

This workshop will focus on the importance of using the DSM IV/Axis II in the treatment of opioid dependent individuals. Strategies for treatment planning, realistic goal setting, and clinical tools will be discussed. An overview of the work of Linehan, Kernberg, Beck, and Masterson will also be provided.

B - 4
Prescription Opioid Dependence

England

Usoa Busto, PhD, Center for Addiction and Mental Health, Toronto, Canada; Steven Clay, DO, Ohio University College of Osteopathic Medicine, Athens, OH; Aaron Gibson, PhD, University of Wisconsin, Madison, WI; Robert Walsh, RAC, NIDA (Facilitator)

Prescription opioid medications can help to improve the quality of life of individuals with severe pain and other medical conditions. However, some of these medications may be abused. The purpose of this workshop is to discuss the nature and extent of the problem of prescription opioid dependence as well as its prevention and treatment.

NIDA Sponsored Workshop

B - 5
Trauma, Addiction and Art Therapy: Connecting the Dots

Scotland A/B/C

Sarah Podolin, LSW, Family Center, Philadelphia, PA; Kate Vandergrift, LPC, Family Center, Philadelphia, PA

This workshop will describe how Art Therapy can be an effective tool for working with women who have a history of trauma and abuse. It will discuss how art therapy can be used to develop connections between verbal and non-verbal memory as well as a means of processing traumatic experiences non-verbally.

The 2004 Policy Maker’s Luncheon on Monday, October 18, is supported through a grant from Bendiner & Schlesinger, Inc.
This plenary session will be moderated by the Honorable Karen Freeman-Wilson, Chief Executive Officer of the National Association of Drug Court Professionals, and the former Attorney General of the state of Indiana. The Honorable Freeman-Wilson is the leading voice of the drug court judges, underscoring the increasing partnership between methadone treatment programs and drug courts throughout the United States. Mr. McDonough will provide an overview of how Florida is responding to the need for improved prevention and treatment access with a focus on evidence-based practices. Mr. McDonough will also focus his remarks on prescription drug abuse and Florida policies, which are aimed at reducing this increasingly pervasive problem. Dr. Condon will focus on NIDA’s leading initiatives to improve treatment quality, emerging from the research conducted in methadone treatment programs and other entities within NIDA’s Clinical Trials Network. Dr. Kreek will draw from her long research history and discuss the scientific underpinnings for our field’s work and what to expect for the future.

WORKSHOP SESSIONS

**C - 1 Improving Services and Increasing Patient Satisfaction through the Establishment of a Patient Advisory Committee**

Great Hall North

Ronald Ingram, MSW, Albert Einstein College of Medicine, Bronx, NY; Leonard Gil, Albert Einstein College of Medicine, Bronx, NY; Patti Juliana, MSW, CSW, Albert Einstein College of Medicine, Bronx, NY

This workshop will present a model for establishing Patient Advisory Committees (PACs) in clinic settings; discuss barriers to implementation and potential solutions; and describe how patient input is gathered, analyzed, and used in program planning, performance improvement, organizational advocacy efforts, and resource development.

*Note: Basic Track*

**C - 2 Pharmacotherapy during Pregnancy: Methadone, Buprenorphine, and Neonatal Abstinence Syndrome**

Great Hall Center

Karol Kaltenbach, PhD, Jefferson Medical College, Philadelphia, PA; John McCarthy, MD, Bi-Valley Medical Clinic, Sacramento, CA; Hendree Jones, PhD, Johns Hopkins University, Baltimore, MD

This workshop will address maternal and infant outcomes utilizing methadone and buprenorphine pharmacotherapy. Presenters will discuss the relationship of maternal methadone dose and neonatal abstinence, maternal and infant outcomes for women treated with up to 190mg of methadone per day, and the safety and efficacy of using buprenorphine during pregnancy.

**C - 2 Methadone Maintenance Treatment in Prison: Evaluating a Pilot, Expanding an Intervention**

Scotland A/B/C

Holly Catala, JD, Beth Israel Medical Center, New York, NY

This workshop will provide an overview of opioid maintenance treatment in prison settings around the world, describe findings and recommendations from evaluation of the first year of a pilot maintenance program in a prison in Puerto Rico, and suggest the implications for expanding prison-based opioid maintenance programs elsewhere.
This workshop will discuss how counselors can help integrate the treatment of psychiatric disorders into the methadone treatment program. We will discuss addictive behavior and coexisting psychiatric problems, barriers to addressing them, how to educate patients appropriately, how to prioritize treatment tasks, and how to work with physicians around psychotropic medication.

* Note: Basic Track

Using Buprenorphine in Opioid Treatment Programs: An Exploration of the Situation

Allan Cohen, MA, Bay Area Addiction Research and Treatment, Sherman Oaks, CA; Leslie Amass, PhD, Friends Research Institute, Los Angeles, CA; Robert Lubran, MS, CSAT, Rockville, MD

Buprenorphine is the newest medication approved by the FDA for the treatment of opioid dependence. Currently, there are increasing interest and efforts to expand the use of buprenorphine into OTP. This workshop will explore buprenorphine as well as the significant challenges that OTP providers must address to offer buprenorphine as a treatment option in their programs.

Reawakening the Creative Spirit, Utilizing Music and Other Art Forms for Advocacy, Outreach and Enhancing the Treatment Experience

Rebecca Boss, MA, LCDDR CODAC, Providence, RI; James Gillen, ACDP, CODAC, Providence, RI; Carrie Blake, RICares, Coventry, RI

Our music outreach program, the “CODAC All-Stars,” allows patients to share their recovery in a unique venue that reinforces the belief that they have something to offer. This workshop will demonstrate approaches and activities that promote creative expression leading to enhanced treatment engagement, satisfaction, and improved collaboration with other treatment providers.

Illicit Substance Use in Treatment: A Retention-Focused Approach

Sharon Stancliff, MD, Harlem East Life Plan, New York, NY; Joanne King, MS, Harlem East Life Plan, New York, NY; Stuart Stein, MBA, Harlem East Life Plan, New York, NY

Many patients continue using illicit drugs, sometimes for years. Presenters will provide administrative and medical perspectives on policies promoting retention among inner-city clinic patients with high rates of medical, psychiatric, and social co-morbidities. Case presentations will illustrate applications to dose adjustments, cocaine use, drug injection, and illicit benzodiazepine use.

Seeking Safety: A Model for Treating Trauma and Opioid Dependence

Marshall Rosier, MS, Connecticut Counseling Centers, Inc., Waterbury, CT; Alan Nolan, LCSW, Connecticut Counseling Centers, Inc., Waterbury, CT; Diane Heyward, MS, Connecticut Counseling Centers, Inc., Waterbury, CT

This workshop will highlight the essential integration of the Seeking Safety model into the dynamic environment of a methadone maintenance program. An overview of the fundamental principles, treatment goals, central ideas and additional features of this treatment model will be presented.
### Poster Sessions

**Monday, October 18, 2004**

- **P1** Knowledge and Beliefs about Methadone among Staff Working in a Therapeutic Community  
  *Siara Andrews, PsyD*

- **P2** Hepatitis Immunization Program for North Carolina OTP's: A Follow-Up  
  *Bert Bennett, PhD*

- **P3** Access to Treatment-Related and Ancillary Services in Opioid Treatment Programs  
  *Nancy D. Berkman, PhD*

- **P4** Developing a Group Treatment Model that Works for Dual Diagnosed Women in M.T.P.  
  *M. Elizabeth Bredin, LICSW*

- **P5** The Interrelationships between Length of Stay, Methadone Dosage, and Age at an Urban Opioid Treatment Program  
  *L.S. Brown, MD, MPH*

- **P6** Role of Attention Deficit Disorder in Methadone Treatment Outcome  
  *Gregory A. Carlson*

- **P7** Patterns of Drug Use vs. Frequency of Urine Drug Screens: What is Cost Effective  
  *Gregory A. Carlson*

- **P8** Self-Reported Drug Use: Retrospective Data Collection of Patients Seeking Methadone Treatment  
  *Daren Carroll, CADC*

- **P9** Enhancing the Care of Hospitalized Opioid Dependent Patients  
  *Brenda Chabon, PhD*

- **P10** Prescription Opioid Abuse in Patients Admitted to a Methadone Maintenance Program  
  *James S. Dorsey, MD*

- **P11** Drug Treatment Demand  
  *Manca Drobne*

- **P12** Evidence-Based Treatments for Opioid Dependence: Clinician Awareness and Program Adoption  
  *Lori J. Ducharme*

### Poster Author Session

**Tuesday, October 19, 2004**

- **P13** Successfully Integrating Treatment Services for Co-Ocurring Disorders  
  *Robert C. Lambert, MA*

- **P14** The Assessment and the Comparison of the Clinical and Sociodemographic Characteristics Among Male and Female Heroin Users  
  *Barbara Lovrecic, MD*

- **P15** Women and Drugs  
  *Mercedes Lovrecic, MD*

- **P16** Methadone and Cardioprotection  
  *Robert Maslansky, MD*

- **P17** Developing a Hepatitis A & B Vaccination Program within an Outpatient Opioid Treatment Program  
  *Paul McLaughlin*

- **P18** Principles of Safe and Adequate Dosing with Methadone  
  *J. Thomas Payte, MD*

- **P19** What are the Odds? Drug Use Among Pregnant Women in Medication Assisted Treatment  
  *Sarah Rockwell Podolin, LSW*

- **P20** State Regulations on Opioid Treatment Providers Three Years after Federal Regulatory Reform  
  *Deborah Podus, PhD*

- **P21** Addiction Specialists’ Attitudes and Prescribing Patterns with Buprenorphine in the First Year of Its Availability: Results of a National Study  
  *Arlene Stanton, PhD, NCC*

- **P22** The Opioid Treatment Program Accreditation Evaluation: An Overview of the Project and Early Findings  
  *Namratha Swamy, PhD*

- **P23** Co-locating Buprenorphine and Methadone Maintenance Treatment: Challenges and Opportunities  
  *Susan Whitley, MD*
Introduction to the Awards Program

The Nyswander/Dole “Marie” Award is a moving tribute to those colleagues who have been nominated and selected by their peers for extraordinary service in the opioid treatment field. The Nyswander/Dole “Marie” Award will be presented by:

Dr. Elizabeth Khuri
Weill Medical College of Cornell University
New York Presbyterian Hospital

Dr. Mary Jeanne Kreek
The Rockefeller University

Dr. Joyce Lowinson
The Rockefeller University

The 2004 American Association for the Treatment of Opioid Dependence Conference recognizes outstanding contributions to opioid treatment by awarding the Nyswander/Dole “Marie” Award to the following individuals:

Cynthia E. Aiken, MS Alaska
Ms. Aiken has had an extraordinary impact in the treatment of opiate addicted patients in Alaska for 25 years. As the Executive Director of the Narcotic Drug Treatment Center, Ms. Aiken has been instrumental in developing a positive, structured program based on behavioral contracting. For the past 4 years, she has been the co-chair of the Annual School of Addictions, the state’s largest meeting of substance abuse workers. In 1992 she helped found and became the Vice President of the Regional Alcohol and Drug Abuse Counselor Training Program, which is a program that trains substance abuse counselors from all over the state. Ms. Aiken truly believes in the success of methadone treatment and has made it her life work to improve the quality of treatment by educating those who hinder this method of treatment.

Nermana Mehić-Basara, MD Bosnia & Herzegovina
Dr. Mehić-Basara is the Director of the Public Institute for Alcoholism and Substance Abuse and leader of the methadone maintenance and detoxification program of Canton Sarajevo, Bosnia and Herzegovina. Dr. Mehić-Basara has demonstrated outstanding dedication to the clinical treatment and education of addicted individuals by organizing and conducting specialty courses regarding drug dependence and appropriate treatment regimens, training, and conferences for more than 20 years. She was also actively involved in the creation of the Mental Health Programs before and after the war in Bosnia and Herzegovina. In addition, she is a member of the editorial board of the magazine Odvisnosti – Addiction – Ovisnosti – Zavisnosti and one of the founding members of the establishment of the South Eastern European Addiction Treatment Network.

David C. Marsh, MD Vancouver, Canada
Dr. Marsh has been instrumental in establishing and expanding methadone treatment services in Canada for the past 20 years. Dr. Marsh is the Physician Leader of Addiction Medicine at Vancouver Coastal Health Authority and Providence Health Center. For 4 years he headed the Medical Team at the Canadian Centre for Addiction and Mental Health. He was also the principal author of the Best Practices for Methadone Maintenance Therapy on behalf of the Canadian Government. At the University of Toronto, he served as an Assistant Professor in the Department of Psychiatry and Department of Family and Community Medicine. Dr. Marsh has affected the lives of countless patients in gaining access to care throughout Canada.
Robert Maslansky, MD  
New York

Dr. Maslansky is a dedicated, compassionate physician and addiction treatment researcher who is committed to the treatment of opioid dependence and has been a pioneer in the methadone field for more than 35 years. Dr. Maslansky established the first methadone clinic in Minneapolis in 1969 by educating and advocating in the Minneapolis community about the benefits of methadone treatment. He further promoted the treatment of the addicted person as the Director of the Medical Education at Cook County Hospital. Dr. Maslansky was a powerful vocal defender of methadone treatment when it came under intense scrutiny by the former mayor of New York City, in spite of significant political risk. He was also a participant in the development of the New York City Health and Hospital Best Practices Manual. Currently, he is the Medical Director of the Addiction Rehabilitation Program at Bellevue Hospital.

Laura F. McNicholas, MD  
Pennsylvania

Dr. McNicholas joined the Methadone Maintenance Program at the Philadelphia Veterans Administration (VA) Medical Center in 1992 after completing her Psychiatry residency at the University of Pennsylvania, as well as a Fellowship in Clinical Research in Substance Abuse. She assumed the responsibilities of Director of the Center of Excellence for Substance Abuse Treatment and Education in the VA, Philadelphia, as well as the Director of Education for the Penn/VA Center on Studies of Addiction. She has been at the forefront of training clinicians to provide pharmacotherapy for opioid dependence as a faculty member of the Psychiatry Residency Program and active in the research fellowship programs in the VA and the Penn/VA Center. Dr. McNicholas also chaired the Center for Substance Abuse Treatment’s Consensus Panel on Clinical Guidelines for the use of buprenorphine in treatment of opioid dependence and serves as a consultant to the Food and Drug Administration and the Federation of State Medical Boards.

Michael Rizzi  
Rhode Island

Mr. Rizzi has been a treatment professional in the substance abuse service field since 1969. As the President/CEO of CODAC Behavioral Healthcare, Mr. Rizzi has been instrumental in the development and implementation of substance abuse treatment, prevention, and education services including methadone treatment at the Rhode Island State Prison. He is the Chair of the Opiate Treatment Association of Rhode Island. He also serves on the committees to re-write State licensing standards, and local community prevention task forces and is a member of the Board and Treasurer of the American Association for the Treatment of Opioid Dependence (AATOD), chairs AATOD’s International Committee, and is AATOD’s immediate past representative on the Joint Commission on Accreditation of Healthcare Organizations’ Professional and Technical Advisory Committee. He has been a tireless advocate to improve the quality of patient care and is a founding member of AATOD.

Richard Schottenfeld, MD  
Connecticut

Dr. Schottenfeld serves as a faculty member at the Yale University School of Medicine, as Master of the Davenport College, and as Director of the Substance Abuse Center at the Connecticut Mental Health Center. For the past 20 years, Dr. Schottenfeld has dedicated his professional career to the research and treatment of opioid addicts and other substance abusers and has been a tireless advocate for methadone treatment. He was instrumental in integrating science-based research practices into the clinical setting during his tenure at the APT Foundation and is currently the Principal Investigator for six research studies. He serves on the editorial boards of numerous journals and has written extensively, contributing to the body of scientific knowledge, including articles in peer reviewed journals, books and other texts related to drug abuse. His extraordinary efforts have had an incredible impact on the field to improve the quality of patient care.
Robert P. Schwartz, MD  
Maryland

Dr. Schwartz has been a constant and commanding proponent of methadone maintenance treatment for 14 years. As a treatment provider, researcher, and advocate, he has been successful at increasing access to methadone maintenance treatment in both the community and the jails. He has improved the quality of care provided to methadone maintained patients by integrating primary care and methadone maintenance treatment. As the Program Officer for the Open Society Institute, Dr. Schwartz promotes the welfare of opioid dependent individuals through approving funding for projects that support the use of methadone and points to best practices in methadone treatment. He is also the Medical Director of Friends Research Institute, where the research projects explore the effectiveness of treatment services and treatment protocols for substance abuse treatment patients.

Marta Torrens, MD  
Barcelona, Spain

Dr. Torrens began working in the drug abuse field in 1986. During 1991 when the use of replacement pharmacotherapies became available in Spain, Dr. Torrens was responsible for the methadone program of the Hospital del Mar. This program has been a teaching program for quality methadone maintenance treatment for many years. She has been invited to scientific congresses and meetings as an expert in the field and is also a member of the work group on clinical guidelines for methadone maintenance treatment. Her groundbreaking research on methadone treatment has focused on factors related to retention in treatment, effectiveness of methadone in health related quality of life, clinical usefulness of methadone plasma levels, and psychiatric comorbidity. She has been one of Spain's leading advocates for methadone treatment, especially critical in times of great challenge.

Richard Weisskopf  
Illinois

Mr. Weisskopf has been an advocate for professional and accessible methadone maintenance treatment services in Illinois for more than 25 years. Mr. Weisskopf began his career in 1978 as a compliance officer for the Illinois Dangerous Drugs Commission. In 1984, the Commission merged with the Illinois Division of Alcoholism to form the new Illinois Department of Alcoholism and Substance Abuse. With the creation of this new state department, he was appointed both Chief of Licensing for all of Illinois’ publicly funded substance abuse treatment programs, and Manager of the Illinois State Methadone Authority. He continues to serve in these capacities and is responsible for administrative oversight of Illinois’ methadone maintenance treatment programs and the primary liaison for opiate treatment issues. He is a principal in the inception of a mobile methadone unit in the Chicago area and is currently leading a statewide effort to ensure that halfway houses and residential centers accept patients with prescribed methadone. He is respected by treatment providers throughout the state for his consistent advocacy on behalf of the patients.

The 2004 Awards Banquet is supported through a grant from Mallinckrodt, Inc.
Wednesday, October 20, 2004

WORKSHOP SESSIONS

E - 1
Ethnic and Cultural Considerations in the Clinical Management of Mental Illness and Substance Abuse  
Great Hall North
Beny J. Primm, MD, Addiction Research and Treatment Corporation, Brooklyn, NY;  
Annelle B. Primm, MD, Department of Psychiatry and Behavioral Sciences, John Hopkins Hospital, Baltimore, MD
This presentation will provide participants with an understanding of the complexities of clinical care of mental illness and substance abuse in members of the four major underserved and underrepresented ethnic and racial groups in the United States.
* Note: Basic Track

E - 2
Accreditation of Opioid Treatment Programs: Findings from the Pilot Study  
Great Hall Center
Jennifer J. Kasten, MSW, RTI International, Raleigh, NC; Wendee Wechsberg, PhD, RTI International, Raleigh, NC
Between 1998 and 2003, CSAT funded a large-scale study to evaluate the impact of accreditation on practices in opioid treatment programs. This workshop will present quality of care findings, accreditation outcomes, organizational changes after pursuing accreditation, and the ability of OTPs to meet the complex demands of opioid maintenance treatment.

E - 3
Evidence-Based Interventions for Difficult Clinical Challenges  
Ireland A/B/C
Michael McCann, MA, Matrix Institute, Los Angeles, CA; Dan George, Matrix Institute, Los Angeles, CA; Albert Hasson, MSW, Matrix Institute, Los Angeles, CA
HIV risk behaviors, stimulant abuse, and poor attendance are among the most taxing clinical problems counselors must address. Presenters will describe specific interventions including a women’s group targeting HIV risk behaviors, the Matrix Model for stimulant use, and a low cost contingency management procedure to improve attendance.

E - 4
Spirituality and Opioid Treatment  
England
Lisa Cook, LSW, Drug Addiction Services of Hawaii, Honolulu, HI; Marcia Tsue Horiuchi, MSW, Drug Addiction Services of Hawaii, Honolulu, HI; Sarah Kelaula Carter, Kumu, Drug Addiction Services of Hawaii, Hilo, HI
OTPs can fall into the trap of holding the regulations and medication management as the core of the program. This workshop will describe culturally based programming and full integration of spirituality in all aspects of management, corporate values, decision making, assessment, treatment interventions, outcomes and program curriculum.

E - 5
A Model for Developing, Implementing, and Integrating Patient Advisory Committees in Opioid Treatment Programs  
Scotland A/B/C
Robert E. Sage, PhD, Addiction Research and Treatment Corporation, Brooklyn, NY; Monica A. Joseph, CSW, Addiction Research and Treatment Corporation, Brooklyn, NY; Ralph J. Savarese, MEd, Addiction Research and Treatment Corporation, Brooklyn, NY
Patient Advisory Committees (PAC) are valuable mechanisms to strengthen managerial and programmatic decision-making, while enhancing patient input and feedback. This workshop demonstrates a practice-based approach that identifies the role and the integration of management, clinical staff and patients in establishing and sustaining the PAC and achieving established objectives.
**WORKSHOP SESSIONS**

**F - 1**  
**Motivating the Unmotivated-Increasing Program Compliance Through a Treatment Motivational Track (TMT)**  
Great Hall North  
Raymond Pomm, MD, River Region Human Services, Inc., Jacksonville, FL; Gloria Hanania, CAP, River Region Human Services, Inc., Jacksonville, FL; Clara Colon, CAP, River Region Human Services, Inc. Jacksonville, FL  
This workshop will review pertinent historical treatment/risk data regarding outcome in a traditional MMTP setting. We will introduce the TMT as an alternative treatment option for those who are not motivated and/or have not satisfactorily progressed in traditional MMTP. Finally, we will review treatment outcomes and patient responses to TMT.

*Note: Basic Track*

**F - 2**  
**Opioid Dosage Database: Continuity of Care in Emergencies**  
Great Hall Center  
Henry Bartlett, COMPA, Albany, NY; Edward Higgins, MA, JSAS Health Care, Inc. Toms River, NJ; Paul McLaughlin, MA, Hartford Dispensary, Hartford, CT  
The lack of a reliable, verifiable regional dosage database seriously compromises emergency readiness. This workshop will describe the stakeholder process (including CSAT, SMAs, and the provider and patient communities from NY, NJ, and CT) and provide recommendations for developing a regional dosage database using an innovative and potentially replicable, secure Web-based system.

**F - 3**  
**Accreditation, Advocacy, and Patients in MAT**  
Ireland A/B/C  
James P. Connolly, CMA, PA-NAMA and NAMA, Newtown, PA; Rebecca Ballard, CMA, OKNAMA, Tulsa, OK; Carolyn Miranda, CMA, NAMA Southern California, Fountain Valley, CA  
Changes in the service environment of MAT, especially accreditation, are affecting relationships of patients, providers, and outside agencies. A panel of NAMA advocates will describe experiences with patient committees, staff advocacy for patient needs, and perceptions of accreditation so far.

**F - 4**  
**Using Simple Microsoft Office Tools to Track, Measure, and Report Patient Outcomes**  
England  
Lawrence O'Toole, MA, Habit Management, Inc., Boston, MA; Carol Wertheimer, PsyD, Melrose-Wakefield Hospital, Lynn, MA  
Learn how to integrate Microsoft Excel and Word to track and document patient outcomes, improve treatment, create reports, and meet licensing and accreditation requirements. All participants will receive software that automatically creates tables, graphs, and charts from simple data entered by program staff. Presenters will demonstrate how the software works and how participants can use the software tools within their clinics.

**F - 5**  
**Contingency Management Approach: Implementation and Outcomes**  
Scotland A/B/C  
Peter Coleman, MS, New York City Health and Hospitals Corporation, New York, NY; Scott Kellogg, PhD, The Rockefeller University, New York, NY; Marylee Burns, MED, New York City Health and Hospitals Corporation, New York, NY  
Presenters will describe how a large municipal hospital system collaborated with researchers to implement a contingency management approach within its methadone treatment programs. Presenters will also discuss the exciting results of this initiative: galvanized and empowered staff, patients with increased motivation to participate in the recovery process, and dramatically changed patient expectations and clinic environments.

---

**CLOSING PLENARY SESSION**

**Treating the Whole Person: Ensuring the Physical, Mental, and Spiritual Health of Those Recovering from Opioid Dependence**  
Great Hall North/Center  
Annette B. Pimm, MD  
Department of Psychiatry and Behavioral Sciences, Johns Hopkins Hospital, Baltimore, MD  
Beny J. Pimm, MD  
President, Addiction Research and Treatment Corporation, Brooklyn, NY  
J. Thomas Payte, MD  
Conference Chair, Colonial Management Group, Orlando, FL  
Mark W. Perrino, MPA  
President, American Association for the Treatment of Opioid Dependence, New York, NY

---

Addiction affects the biological, psychological, and social self of methadone patients who seek recovery. No less important to the life sustaining recovery of methadone patients is the attention to the spiritual self. Dr. Beny Pimm and Dr. Annette Pimm will provide a comprehensive understanding of how all of these issues interrelate when providing treatment to the patient and increasing the chances of leading to a meaningful life of recovery.

---

American Association for the Treatment of Opioid Dependence
Exhibitor Directory

Accel Software Engineering — Booth 307
449 Maple Avenue
Pittsburgh, PA 15218
Ph: 724-733-8800
Fx: 724-733-8820
cplinta@accelse.com
www.accelse.com

Addiction Management Systems, Inc. — Booth 206
36-40 37th Street
Long Island City, NY 11101
Ph: 800-473-9599
Fx: 718-786-2116
www.addictionmanagement.com
Addiction Management Systems pioneered the development of Automated Dispensing and Clinical Management software for Methadone-LAAM programs. Currently AMS services more than 220 clients. A full range of the company's software, including the new SQL version, new clinical management modules sensitive to CARF, JCAHO and HIPAA requirements, as well as billing products will be presented.

American Association for the Treatment of Opioid Dependence — Booth 109
217 Broadway Suite 304
New York, NY 10007
Ph: 212-566-5555
Fx: 212-349-2944
aatod.mail@verizon.net
www.aatod.org
The American Association for the Treatment of Opioid Dependence (AATOD) was founded in 1984 to enhance the quality of patient care in treatment programs by promoting the growth and development of comprehensive methadone treatment services throughout the United States. AATOD works with federal agencies, state substance abuse authorities and agencies within the criminal justice system concerning opioid treatment policy in addition to coordinating activities with advocacy groups and treatment providers in all regions of the country. AATOD continues to work on behalf of all its members by providing the most current policy papers, national advisories, research reviews, special surveys and conference/training event announcements.

Ammon Analytical Laboratory, LLC — Booth 107
1622 South Wood Avenue
Linden, NJ 07036
Ph: 908-862-4404
Fx: 908-862-4405
ammontox@aol.com
www.ammontox.com
Toxicology Services that are designed specifically for Methadone Treatment Programs. Ammon Analytical is a specialty laboratory that primarily serves MMTPs. Our staff has extensive experience in servicing and providing solutions to the unique needs of Methadone Programs. Because of our experience, we can solve most of the problems that Treatment Programs encounter with typical medical laboratories.

BCI Management Systems Inc. — Booth 310
1064 N. Market
Wichita, KS 67214
Ph: 316-263-2155
Fx: 316-263-7147
mdicker265@aol.com

BCI Management Systems offers user friendly computer software that was developed in an operating C.A.R.F. certified methadone maintenance clinic by clinical staff. The management system includes the computer system, software, set-up and training at a reasonable cost. Demonstration software is available at the booth.

Bendiner & Schlesinger, Inc. — Booth 106
47 Third Avenue
New York, NY 10003
Ph: 212-254-2300
Fx: 212-358-9076
fhartigan@bendinerlab.com
www.bendinerlab.com
Bendiner & Schlesinger, Inc. (est. 1843) is a full-service laboratory with 35 years experience in meeting the testing needs of treatment programs for opioid dependence throughout the U.S. Bendiner & Schlesinger, Inc. offers laboratory-based, oral-fluid or urine drug screening, including differentiation and quantitation of positive screens of either specimen type.

CARF — Booth 202
4891 E. Grant Road
Tucson, AZ 85712
Ph: 520-325-1044
Fx: 520-318-1129
bharrison@carf.org
www.carf.org
Over 3000 organizations (28,000 programs) have earned CARF accreditation. Over 10,000 of these programs are accredited under the Behavioral Health Customer Service Unit, and represent 900 organizations in the United States and Canada. Stop by the CARF exhibit to learn more about its accreditation opportunities, and how accreditation can help with continuous quality improvement.

Cebert Pharmaceuticals, Inc. — Booth 103
1200 Corporate Drive, Suite 370
Birmingham, AL 35242
Ph: 205-981-0201
Fx: 205-981-0279
jwatkins@cebert.com
www.cebert.com
Cebert Pharmaceuticals, Inc. provides the following Methadone products: Diskets®, Cherry & Clear Liquid and Powder. We also offer several accessories to help serve your clinic's needs. Our Back to Life Counseling Videos/Workbooks, our new Methadone-specific Online CME Credits, take-home bottles and more are available to assist you in meeting the demands of the Methadone community. Convenient, one-stop shopping, combined with timely, efficient and consistent customer service makes Cebert Pharmaceuticals THE Methadone provider of choice. Please come by our booth or visit us online at www.cebert.com.
Exhibitor Directory

Centre for Addiction and Mental Health — Booth 203
33 Russell Street
Toronto, ON M5S 2S1 Canada
Ph: 416-595-6059
Fx: 416-593-4694
marketing@camh.net
www.camh.net
The Centre for Addiction and Mental Health (CAMH) publishes practical, research-based resources for healthcare professionals. We transform our leadership and commitment in research, treatment and education into publications that address the full continuum of care, from prevention to treatment. CAMH is a PAHO/WHO Collaborating Centre.

Comstock Computing L.L.C. — Booth 211
7118 Langdon Lane
Houston, TX 77074
Ph: 713-774-3220
Fx: 208-567-1746
sales@methware.com
www.methware.com
Comstock Computing provides superior software and hardware solutions. With over 25 years experience providing software to the field and groundbreaking technology such as the Welcome Station®, Comstock Computing has the technology, commitment, know how and hands on experience that no one else can match.

Creative Socio-Medics — Booth 110
3500 Sunrise Highway, Suite D-122
Great River, NY 11739
Ph: 631-968-2026
Fx: 631-968-2123
marge@csmcorp.com
www.csmcorp.com
Creative Socio-Medics Corp. is a leading provider of methadone clinic management systems in the US, Canada, and the UK. Creative’s Avatar AM system is built for ease of use by nurses and is scaleable to multiclinic networks.

Dade Behring — Booth 401
1717 Deerfield Road
Deerfield, IL 60015
Ph: 847-267-5300
Fx: 847-236-7101
jeannie_henson@dadebehring.com
www.dadebehring.com
Syva Company, the manufacturer of Emit® Immunoassays, the world’s leading drug monitoring methodology, offers a comprehensive portfolio of products for drugs of abuse, specimen validity, therapeutic drugs, and point of care testing. Syva brand products have been used for more than 32 years, and its reputation as the Gold Standard stands strong.

Eastside Clinic — Booth 212
445 E. Sherman Road
Muskegon Heights, MI 49444
Ph: 231-206-1917
Fx: 231-733-6151
drsmith@eastsidesc.com
www.eastsidesc.com
This is a comprehensive automated computer dispensing system designed for methadone treatment programs. It features third-party billing, counseling, record keeping with ASI, time/attendance, medical records with closing records, methadone inventory, intra-office e-mail and more; making any clinic paperless. Little or no training required. Check it out.

Friends Medical Laboratory, Inc. — Booth 304
5820 Southwestern Blvd
Baltimore, MD 21227
Ph: 410-247-4417
Fx: 410-247-4426
lisanneg@friendslab.com
www.friendslab.com
Friends Medical Laboratory (FML) is a toxicology laboratory that has been performing drug testing since 1963. In 1968 FML began testing for methadone programs. FML offers a wide range of testing for drugs of abuse. They can test urine and oral fluid samples as well as offer confirmations of any pre-screening instant kits. FML has recently begun offering point of care or instant drug testing kits for both urine and oral fluids.

Global Medical Systems Inc. — Booth 300
660 Baker Street, Suite 350
Costa Mesa, CA 92626
Ph: 714-432-7381
Fx: 714-432-7503
www.xpressdrugtest.com
International Diagnostic Systems Corp. — Booth 302
2620 S. Cleveland Avenue, Suite 100
St. Joseph, MI 49085
Ph: 269-428-8400
Fx: 269-428-0093
jstrine@ids-kits.com
www.ids-kits.com
IDS develops, manufactures, and markets ELISA test kits for detecting drugs in hair, blood, serum, plasma, oral fluids, urine, and other matrices for the forensics market. Product types include Buprenorphine, Generic Opiates, Selected Opiates, Hydrocodone, Oxycodeone, Mepedrine/Normeperidine, Naltrexone, Fentanyl, and 20 more. Reagent Rental for Equipment available.

Joint Commission (JCAHO) — Booth 111
One Renaissance Blvd.
Oakbrook Terrace, IL 60181
Ph: 630-792-5790
Fx: 630-792-4790
mcesare-murphy@jcaho.org
www.jcaho.org
Accreditation from JCAHO is a “gold seal of quality” and a mark of distinction for accredited behavioral health care organizations. Most importantly, Joint Commission Accreditation helps to ensure that your organization is delivering the best quality of care and services to your clients and their families.
Kols Containers/O.Berk of New England — Booth 213
1408 DeSoto Road
Baltimore, MD 21230
Ph: 800-457-5657
Fx: 410-646-5671
jlineberry@kolscontainers.com
www.kolscontainers.com
Kols Containers and O.Berk New England are full line container distributors of glass and plastic bottles and jars in a variety of sizes. Both companies stock methadone take-home bottles and child resistant caps in large quantities at our respective warehouses in Baltimore, MD and New Haven, CT.

Mallinckrodt Pharmaceuticals — Booth 207
675 McDonnell Blvd.
P.O. Box 5840
St. Louis, MO 63134
Ph: 800-325-8888
Fx: 314-654-7128
mike.neely@tycohealthcare.com
www.mallinckrodt.com
Mallinckrodt Pharmaceuticals will present its complete line of Methadone products including Powders, Oral Concentrate (cherry flavored and sugar-free), 40mg. Dispersible Tablets, and 5 and 10mg. Tablets. New this year, Mallinckrodt will introduce innovative dispensing equipment and a suite of products and services for drug screening.

Manisses Communications — Booth 309
208 Governor Street
Providence, RI 02906
Ph: 401-831-6020
Fx: 401-861-6370
jhamel@manisses.com
www.manisses.com
Manisses Communications Group, Inc. is a leader in the development and dissemination of reliable mental health and addiction information. Established in 1984, our company publishes eight newsletters, countless books and white papers, industry directories and two state-of-the-art, full-color magazines that bring you vital news, research and best practices information on an ongoing basis.

National Association of Drug Court Professionals – Booth 405
4900 Seminary Road, Suite 320
Alexandria, VA 22311
Ph: 703-575-9400
Fx: 703-575-9402
www.nadcp.org

National Institute on Drug Abuse — Booth 113
6001 Executive Blvd., Suite 5213
Bethesda, MD 20892
Ph: 301-594-6142
Fx: 301-443-7397
jn34d@nih.gov
www.drugabuse.gov
The National Institute on Drug Abuse is a Federal agency charged with supporting research on the causes, prevention, and treatment of all aspects of drug abuse including AIDS. The results of the NIDA-funded research offer this country’s best hope for solving the medical, social, and public health problems of drug abuse and addiction. Publications and research opportunities supporting these efforts will be made available.

National Opioid Treatment Clinicians Association (NOTCA) — Booth 311
209 A Swanton Way
Decatur, GA 30030
Ph: 404-862-7195
Fx: 404-377-8536
elaine@notca.com
www.notca.com
The National Opioid Treatment Clinicians Association (NOTCA) is a national certification body that provides certifications for qualified applicants in the areas of counseling, supervision and nursing. NOTCA is a NAADAC Approved Education Provider that utilizes counselors, supervisors, program directors, nurses and physicians within opioid treatment setting to conduct trainings annually.

Netalytics — Booth 101
710 Pettigru Street
Greenville, SC 29601
Ph: 864-242-9423
Fx: 864-242-2971
methasoft@netalytics.com
www.methasoft.com
Netalytics provides a new level of sophistication in addiction treatment software. New features include the Scheduler, Methasoft Perspective, and customizable Assessments plus an enhanced Treatment Planner with improved scalability and flexiblility. Methasoft continues to provide unparalleled customer service and a stable, user-friendly product utilizing the latest technology.

Nutritional Supplements Corp — Booth 100
3325 Crossing Court
Birmingham, AL 35242
Ph: 205-936-3423
Fx: 205-995-0671
ATandL@aol.com

OraSure Technologies Inc. — Booth 102
220 East 1st Street
Bethlehem, PA 18015
Ph: 805-869-3538
Fx: 610-882-1830
customerservice@orasure.com
www.orasure.com
NEW from the leader in oral-fluid diagnostics: Intercept® oral-fluid drug and alcohol testing-one, fast, convenient collection for accurate drug and alcohol testing. Oral-fluid eliminates gender issues and specimen collection hassles with greater dignity for your clients and staff. Laboratory analysis provides high accuracy, with fast turn-around on results.

Patient Support & Community Education Project — Booth 210
c/o Long Beach Medical Center – MMC
455 East Bay Drive
Long Beach, NY 11561
Ph: 516-897-1330
Fx: 516-897-1149
Exhibitor Directory

Reckitt Benckiser — Booth 312
10710 Midlothian Tumpike, Suite 430
Richmond, VA 23235
Ph: 804-379-1090
Fx: 804-379-1215
debby.betz@reckittbenckiser.com
www.reckittbenckiser.com

San Diego Reference Laboratory — Booth 200
6122 Nancy Ridge Drive
San Diego, CA 92121
Ph: 858-677-7970
Fx: 858-677-7998
kimberly@sdrl.com
www.sdrl.com
San Diego Reference Laboratory is a client-focused analytical biomedical laboratory, specializing in toxicological and clinical testing services. Our mission is to provide the highest quality testing, superior customer service and competitive pricing to a broad range of clients throughout the United States.

Scientific Testing Laboratories, Inc. — Booth 306
450 Southlake Blvd
Richmond, VA 23236
Ph: 804-378-9130
Fx: 804-379-5919
kmarks@scitest.us

Secon of New England — Booth 403
415 Main Street, 4th Floor
Worriester, MA 01608
Ph: 508-831-0703
Fx: 508-831-0803
www.seconne.com

Smart Management Inc. — Booth 303
66 Pavilion Avenue
Providence, RI 02905
Ph: 401-780-2300
Fx: 401-780-2350
sfaria@smartmgmt.com
www.smartmgmt.com
SMART systems is the operational software used by treatment providers throughout the United States and Europe to treat more than 15,000 patients daily. SMART also provides management services to providers such as Discovery House, with thirteen clinics throughout the United States. SMART’s experience with managing multiple facilities provides the strategic advantage of offering the singular product best suited to the comprehensive treatment of substance abuse patients.

Substance Abuse and Mental Health Services Administration — Booth 308
11420 Rockville Pike
Rockville, MD 20852
Ph: 240-747-4821
Fx: 240-747-5466
SAMHSA is the Federal agency charged with improving the quality and availability of prevention, treatment, and rehabilitative services in order to reduce illness, death, disability, and cost to society resulting from substance abuse and mental illnesses. We will display free resources on these issues.

Tower Systems, Inc. — Booth 313
17461 Irvine Blvd. Suite Y
Tustin, CA 92780
Ph: 714-731-0491
Fx: 714-731-8634
info@towersys.com
www.methadoneclinics.com
Choosing once again not to jump on any of the latest “here today, gone tomorrow” technological bandwagons, Tower Systems has been committed to producing sound and stable software for methadone clinics that is versatile and mature enough to meet the changing needs of a changing industry. If its functionality you’re looking for, look no further than the TBS-Clinic II Methadone Management Software package.

Treatment Software Solutions — Booth 205
P.O. Box 1791
Rockville, MD 20849-1791
Ph: 301-762-2360
Fx: 301-762-2365
david.stiles@clinicweb.net
www.clinicweb.net
Treatment Software Solutions combines state-of-the-art technology with a thorough understanding of the needs of today’s OTPs. ClinicWeb is a powerful, reliable, and easy-to-use clinical management solution in use by satisfied customers across the United States. Please visit our booth for a complete demonstration.

VistaPharm, Inc. — Booth 201
2224 Cahaba Valley Drive, Suite B3
Birmingham, AL 35242
Ph: 205-981-1387
Fx: 205-980-4849
info@vistapharm.com
www.vistapharm.com
VistaPharm manufactures and distributes of a full line of quality methadone products. We offer oral concentrate, 40mg dispersible tablets, 10mg tablets and powder. Our personalized service sets us apart and we are accessible to address your needs in an expedient manner. Stop by our booth to see our new plastic bottles!
Conference Notes

- Smoking is prohibited at all conference events.
- Your conference badge is your admission to all events and educational sessions.
- Participation in this conference assumes knowledge and authorization of audio and/or video recordings of portions of this conference.
- Part of the proceeds of the sleeping room rates will be used to defray conference-meeting expenses.

Audio Taping Information

Don’t Miss A Single Important Word!

As a special service to attendees, the presentations will be available on CD or audiocassette.

With scheduling conflicts and concurrent sessions, Content Management Corp., formerly Audio Archives International, Inc., will make it possible to attend every important session via CD/audiocassette, using advanced techniques ensuring the highest quality recordings.

High-speed duplication equipment eliminates long delays, allowing you to hear the important information shortly after each session has concluded. The CD/cassettes provide an excellent recap and a valuable training tool to those who could not attend.

Look for the Content Management order desk located in the Registration area and take your information home with you, or place an order through the mail after the conference. Please refer to your registration packet for a complete listing of available sessions.

Content Management Corp.
Phone: 818-957-0874
Fax: 818-957-0876

A Special Note for the Disabled

The American Association for the Treatment of Opioid Dependence has taken steps required to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently than other individuals because of the absence of auxiliary aids and services, as outlined in the Americans with Disabilities Act.

Continuing Medical Education (CME) / Continuing Education Units (CEUs)

Continuing Medical Education (CME) units will be awarded by the conference joint sponsor, the American Society of Addiction Medicine (ASAM). Continuing Education Units (CEUs) will be awarded by the Association of Social Work Boards (ASWB), the National Board for Certified Counselors (NBCC), and the National Association of Alcoholism and Drug Abuse Counselors (NAADAC). Applications to award continuing education units/contact hours have been submitted to the American Psychological Association, the New York State Nurses Association, and the Certification Board for Addiction Professionals of Florida (CBAFP).

To apply for CMEs / CEUs, conference attendees must pay the associated fee, either in advance or at the on-site conference registration desk. Attendance at conference events will be verified electronically. Each attendee seeking CMEs / CEUs will have a bar code attached to his/her conference badge. At the end of EACH session (including pre-conference sessions, plenary sessions, all workshops, hot topics sessions, and the poster author session), attendees must have the bar codes on their badges “scanned” by room monitors. These monitors will have electronic equipment that will automatically record each individual’s attendance in a database. The database will track and tabulate each attendee’s CMEs / CEUs. After the conference, certificates documenting attendance and the number of CMEs / CEUs earned will be electronically generated and mailed to all eligible attendees. Attendees participating in all six Basic Track workshops will receive an additional certificate documenting their participation in this special training series.

Questions about CMEs / CEUs can be answered by staff at the Conference CME / CEU Desk, located in the registration area.

Orlando City Information is located at the Hospitality Booth in the Registration Area.
DIRECTIONS TO RECREATION ISLAND & ISLAND RESORT BUILDING

FROM THE HOTEL LOBBY:

PATH 21
• Take elevator to first floor
• Go to open atrium area adjacent to the Disney Shop
• Take tunnel to Recreation Island
• Cross over moat bridge
• Follow sidewalk past tennis court and pool
• Proceed to entrance of Island Resort Building

Or

PATH 22
• Take elevator to first floor
• Go to open atrium area adjacent to the Disney Shop
• Proceed past the Spa to the Spa Courtyard and Fitness Center
• Go left at the street curb along the covered walkway
• Proceed past the Disney Transportation pick-up area
• Continue on the covered walkway over the canal bridge
• Proceed to entrance of Island Resort Building
THINGS TO DO AND SEE IN ORLANDO

The 2004 AATOD Conference Hospitality Committee welcomes you to Orlando, Florida. Regardless of age or vacation wishes, Orlando offers every member of the family a favorite pastime that can be captured forever on film and in fond memories. Orlando captivates visitors with great theme parks and attractions; superb shopping values; art; cultural and historical venues; outdoor adventures; thrilling water parks; diverse dining; entertainment; nightlife; and more.

Whether you are a first-time visitor or a seasoned Orlando vacationer, you can find unique ideas on what to do in Orlando. The Wyndham Palace Resort & Spa is within easy walking distance to the Downtown Disney area, which is the home of La Nouba, a permanent Cirque du Soleil and Pleasure Island. There are many other area attractions including tours of the Orange County Regional History Center, City of Eatonville, Withers-Maguire House and Museum, Historic Waterhouse Residence and Carpentry Shop Museum, and the Wells’Built Museum of African-American History. You can also ride on a “double decker” bus at The Peabody Orlando, smell the roses at Harry P. Leu Gardens, touch a stingray at SeaWorld Orlando, drive a stock car at 125 m.p.h. at Richard Petty Driving Experience, tour the world in under a mile at Epcot, design and ride your own roller coaster at WonderWorks and DisneyQuest, watch golf greats at a national PGA event, go back to the future at Universal Studios, go on an African safari at Disney’s Animal Kingdom, marvel at Tiffany glass at the Charles Hosmer Morse Museum of American Art, and much more.

If shopping is on the schedule, Orlando has a wealth of stores and boutiques for you to peruse. Downtown Orlando offers trendy boutiques and restaurants in Thornton Park while Winter Park is perfect for window shopping and lunching at outdoor cafes on Central Florida’s own “Rodeo Drive” – Park Avenue. At Orlando’s shopping malls, visitors can find the best brands carried at upscale fashion retailers like Neiman Marcus, Bloomingdale’s, Saks Fifth Avenue, Nordstrom, Macy’s, Tiffany’s and Cartier.

If you are a frequent fine diner or have often imagined indulging in a more sophisticated gastronomic lifestyle, Orlando-area restaurants will remind you why dining is not just a pleasure, it’s a way of life. There’s a new rank of restaurants drawing rave reviews on Restaurant Row, which includes Timpano Italian Chophouse, Seasons 52 and Anaelle & Hugo. On the 27th floor of the Wyndham Hotel you can savor exceptional cuisine at Arthur’s 27. The Watercress Café offers casual lakeside dining as well as the ever-popular Disney Character Breakfast buffet.

The Hospitality Committee will have all of the information you need on what to do and how to get there. Clinic Tours can also be arranged for those who are interested in seeing Florida’s Methadone Treatment Community first-hand. Once again, Welcome to Orlando, and we are certain you will enjoy all that Orlando has to offer.
Special Thanks

The American Association for the Treatment of Opioid Dependence and the 2004 Conference Planning Committee acknowledge and give special thanks to:

Addiction Management Systems, Inc.
Bendiner & Schlesinger, Inc.
Cebert Pharmaceuticals, Inc.
Center for Drug Free Living
Creative Socio-Medics
David Szerlip & Associates
Mallinckrodt, Inc.
National Institute of Health (NIH) – National Institute on Drug Abuse (NIDA)
O.Berk Company of New England and Kols Container, Inc.
San Diego Reference Laboratory
Seigfried (USA)
Substance Abuse and Mental Health Services Administration (SAMHSA) – Center for Substance Abuse Treatment (CSAT)
VistaPharm, Inc.

We would especially like to thank our host city, Orlando.

Florida Department of Children and Families – Substance Abuse Program Office
Florida Association for the Treatment of Opioid Dependence
Colonial Management Group, LP
CONTINUING MEDICAL EDUCATION CREDITS

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Society of Addiction Medicine (ASAM) and the American Association for the Treatment of Opioid Dependence.

The American Society of Addiction Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The American Society of Addiction Medicine (ASAM) designates this continuing medical education activity for 24.25 credit hours in Category 1 of the Physician’s Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

CONTINUING EDUCATION CONTACT HOURS

Application has been submitted to the New York State Nurses Association’s Council on Continuing Education, which is accredited by the American Nurses’ Credentialing Center’s Commission on Accreditation, to award up to 33.6 contact hours for this Education Design I activity.

CONTINUING EDUCATION UNITS

American Association for the Treatment of Opioid Dependence, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org, phone: 1-800-225-6880, through the Approved Continuing Education (ACE) program. American Association for the Treatment of Opioid Dependence maintains responsibility for the program.

Social workers will receive 36 continuing education clock hours in participating in this course.

American Association for the Treatment of Opioid Dependence is an approved provider through the National Association of Alcoholism and Drug Abuse Counselors (NAADAC) (Provider Number 000218). This program meets the criteria for 36 contact hours of continuing education.

Application has been submitted to the American Psychological Association to award CEU’s to psychologists.

Application has been submitted to the Certification Board for Addiction Professionals of Florida (CBAPF) to award up to 36 continuing education hours.

Plan to join us again in April 2006